SLC22A4 and chronic myelogenous leukemia, BCR-ABL1 positive: In our previous work, multivariate analysis identified the regulatory SNP rs460089 located in the gene promotor region of drug transporter OCTN1 as being significantly associated with response in CML patients with first-line imatinib treatment [14].